Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Parallel findings in age-related macular degeneration and Alzheimer's disease.
Ohno-Matsui K.
Source
Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Japan. k.ohno.oph@tmd.ac.jp
Prog Retin Eye Res. 2011 Jul;30(4):217-38. doi: 10.1016/j.preteyeres.2011.02.004. Epub 2011 Mar 25.
Abstract
Age is a common risk factor for Alzheimer's disease (AD) and age-related macular degeneration (AMD). Because of the increasing age of the population, these two age-related diseases have recently received a great deal of attention. In addition to age as a risk factor, AD and AMD have many characteristics in common. An important characteristic common to both diseases is the presence of amyloid ß (Aß) in the senile plaques of the AD brain and in the drusen of AMD patients. We have focused on the role of Aß as a key regulator of the progression from drusen to AMD, and our results have shown that Aß causes an imbalance of angiogenesis-related factors in the retinal pigment epithelial (RPE) cells. Mice that lack the Aß-degrading enzyme neprilysin develop RPE degeneration, and the sub-RPE deposits that are formed have features similar to those of AMD in humans. These data suggest that a common pathogenic mechanism might exist between AMD and AD. Thus, therapeutic approaches that have targeted Aß in patients with AD can also be applied to AMD. In this review, we summarise recent findings on the shared characteristics and perspectives between AMD and AD, beginning with the mechanism of Aß deposition and including a discussion of Aß-targeted therapeutic approaches for both AD and AMD.
Copyright © 2011 Elsevier Ltd. All rights reserved.
http://www.ncbi.nlm.nih.gov/pubmed/21440663
Five companies which can find a breakthrough solution for Alzheimer disease- ABT, LLY, JNJ, NVS, PFE
Northern, WI 03/13/2013 (avauncer) – There are five companies poised to find a breakthrough treatment for Alzheimer’s disease. They include the likes of Abbott Laboratories (NYSE:ABT), Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Novartis AG – ADR (NYSE: NVS) and Pfizer Inc. (NYSE:PFE). Each of these companies is involved in research for Alzheimer’s disease that have shown some promise as a future solution.
Abbott Laboratories has a market cap around $55 billion. The Chicago-area based health care products company is conducting research in the area of neuroscience, developing compounds that target brain receptors regulating mood, memory and other functions of the brain. The company currently has 11 compounds in studies for various cognition related conditions including Alzheimer’s disease.
Eli Lilly & Co. is an Indianapolis, Indiana based pharmaceutical product company with a market cap of around $62 billion. The company’s experimental treatment, solanezumab, is part of a federally sponsored study being coordinated by Harvard Medical School. The study will be conducted over 3 years at a cost of $100 million.
Johnson & Johnson, the New Brunswick, New Jersey based healthcare research and development company, has a market cap around $214 billion. The company, in partnership with Pfizer Inc., has developed bapineuzumab designed to change the course of Alzheimer’s disease. The drug is showing some results in the reduction of certain signs associated with Alzheimer’s disease.
Swedish based healthcare solutions company Novartis AG – ADR market cap is around $168 billion. The company’s Exelon Patch (known as rivastigmine transdermal system) used with people that have mild to moderate Alzheimer’s disease has been approved by the U.S. Food and Drug Administration to administer higher doses of the drug to patients.
Finally Pfizer Inc., with a market capitalization of around $201 billion is a New York City based research and biopharmaceutical company. Along with Johnson & Johnson, its bapineuzumab, has shown promise in reducing physical damage in the brain and reduced the buildup of amyloid plaque, which is associated with Alzheimer’s disease.
Shares of Abbott Laboratories (NYSE:ABT) were up by 0.14% to close at $34.98. Shares of Eli Lilly & Co. (NYSE:LLY) were up by 0.02% to close at $55.08. Shares of Johnson & Johnson (NYSE:JNJ) were up by 0.15% to close at $78.56. Shares of Novartis AG – ADR (NYSE:NVS) were up by 0.78% to close at $69.53. Shares of Pfizer Inc. (NYSE:PFE) were down by 1.1% to close at $27.94.
http://avauncer.com/five-companies-which-can-find-a-breakthrough-solution-for-alzheimer-disease-abt-lly-jnj-nvs-pfe-3024
"We continue our efforts to increase public and investor awareness of Intellect through media outreach and other activities, including my participation as presenter at several international industry and investor conferences. These activities also comprise an important component of our business development strategy as it gives us the opportunity to meet potential pharma partners face-to-face. Intellect was selected to give a presentation at BIOEUROPE in Barcelona March 11-13 and I have scheduled several meetings with potential partners. I also am an invited speaker at the Asian Antibody Conference in Singapore, June 17-20."
http://finance.yahoo.com/news/intellect-neurosciences-issues-letter-shareholders-173223118.html
INTELLECT NEUROSCIENCES
CNS/Neurology | 10:00, Tuesday, March 12 | Level 1, Room 120
http://www.ebdgroup.com/bes/presenters/prs_comps.php?carousel_staple
Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
Press Release: Intellect Neurosciences, Inc. – Thu, Feb 28, 2013 9:35 AM EST
NEW YORK, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain.
Dr. Chain's presentation, which begins at 10:00 am local time on March 12th, features the company's CONJUMAB platform technology, including its lead compound, CONJUMAB-A, an antibody drug conjugate being developed for age-related macular degeneration (AMD) as well as the company's tau antibody technology. Dr. Chain will also be attending the 11th Annual Conference on Alzheimer's disease and Parkinson's disease from March 6-10 in Florence, Italy.
"We discovered a novel way to attack certain types of complex diseases through the use of antibody drug conjugates (ADCs) in which two different molecules - an antibody targeting an amyloidogenic polypeptide and a small neuroprotective molecule - are combined chemically into a single entity," said Dr. Daniel Chain, the inventor of CONJUMAB. "The antibody has a chaperone-like role in clearing the amyloid while the small molecule reduces the neurotoxicity caused by the peptide. Our lead drug candidate CONJUMAB-A, capitalizes on recent insights linking the mechanisms that contribute to the pathogenesis of AMD and Alzheimer's disease, especially the role of oxidative stress and amyloid beta (Aß) which is believed to be an essential mediator in the progression of dry AMD to wet AMD."
Traditionally, ADCs have been used to deliver a cytotoxic payload to kill cancer cells. By contrast, drugs based on CONJUMAB are comprised of antibodies targeting amyloidogenic polypeptides that would be linked chemically to a small molecule that is non-toxic and instead confers cytoprotective properties such as an antioxidant or anti-inflammatory molecule. CONJUMAB-A is comprised of a humanized monoclonal antibody against beta amyloid (Aß) conjugated to melatonin, a potent antioxidant molecule with anti-amyloidogenic, anti-inflammatory and anti-apoptotic properties with the aim of preventing the accumulation of toxic Aß in the retina and delivering on-site neuroprotection to reduce geographical atrophy and neovascularization.
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on February 12, 2013 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.
Contact:
Jules Abraham
JQA Partners, LLC
917-885-7378
jabraham@jqapartners.com
http://finance.yahoo.com/news/intellect-neurosciences-present-bio-europe-143500108.html
LONZA Annual Report 2012 tomorrow
http://www.lonza.com/about-lonza/investor-relations/investor-information.aspx
AesRx Management?
Management and Board of Directors:
Stephen R. Seiler — Founder, Chief Executive Officer
Warren C. Stern, Ph.D. — Sr. Vice President of Drug Development
Maggie Flanagan LeFlore, Ph.D — Director
Colin Hill — Director
Mary K. Pendergast — Director
http://aesrx.com/management.html
Key Executives For AesRx, LLC
Mr. Peter Vitruk
Co-founder and General Manager
Mr. Paul Diaz
Co-founder
Mr. Carl Bennett
Director of Sales and Marketing
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=115131722
What's it all about?
Penny Stocks in Queue - Premier Holdings (PINK:PRHL), HEALTHY COFFEE (PINK:HCEI), Endeavor Power, Intellect Neurosciences, China Logistics
Scottsdale, AZ -- (SBWIRE) -- 03/08/2013 -- universalpennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.
Intellect Neurosciences, Inc (PINK:ILNS)’s shares rose, gaining 20.00 percent to close at $0.0120. The stock is down around -7.69% this year and 5% for the last 12 months. Around 256.52 million shares changed hands yesterday, higher from an-average trading volume of 2.2 million shares. Intellect Neurosciences, Inc., a biopharmaceutical company, engages in the discovery and development of proprietary drug candidates for the treatment of Alzheimer?s disease and other diseases associated with oxidative stress.
For How Long ILNS’s Gloss will Attract Investors? Find out via this report
http://www.sbwire.com/press-releases/penny-stocks-in-queue-premier-holdings-pinkprhl-healthy-coffee-pinkhcei-endeavor-power-intellect-neurosciences-china-logistics-219679.htm
Trading Volume March 8, 2013
Intellect Neurosciences (ILNS:OTC US), ISIN: US45822W2098
Regular Volume 677.800 (100%)
Buy 423.700 (15 trades; 62,51%)
Sell 254.100 (5 trades; 37,49%)
Short 293.700 (43,33%)
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
http://otcshortreport.com/index.php?index=ilns&action=view
http://shortvolume.com/
Alzheimer’s Seen on Scans Decades Before Dementia, Study Shows
By Jason Gale - Mar 8, 2013 1:01 AM GMT+0100
Abnormal deposits in the brain thought to trigger Alzheimer’s disease can be detected decades before the memory-robbing illness ensues, a finding that will help guide future treatments, researchers in Australia said.
Doctors at Melbourne’s Austin Hospital followed 200 seniors, including people with Alzheimer’s disease and mild cognitive impairment, for more than three years to chart any decline in cognition and brain size against the deposition of abnormal protein in their brains. They found it takes about 20 years for the deposits, known as amyloid beta, to lead to dementia.
The findings, published today in the medical journal the Lancet Neurology, suggests doctors have a large window of opportunity to potentially slow, or even reverse, the accumulation of amyloid beta to stave off the onset of Alzheimer’s. The disease is the main cause of dementia, which afflicts 35.6 million people globally -- a number the World Health Organization says will double by 2030 and triple by 2050.
“It’s now quite clear that it’s a very slow, gradual process over a couple of decades,” said Christopher Rowe, Austin Hospital’s director of nuclear medicine. For Alzheimer’s to develop, the brain needs to accumulate large amounts of amyloid “and you need it there for a long time,” Rowe, a study co-author, said in a telephone interview from Florence, Italy.
All Alzheimer’s disease patients have amyloid deposits in the brain, though not all people with the deposits have the disease, Rowe said.
Post-Mortem Studies
“We’ve known for a long time from post-mortem studies that apparently normal people can have amyloid in their brain, and it’s been hypothesized that this is representing a slow build up towards Alzheimer’s disease and they just hadn’t developed the dementia by the time that they died,” he said. “It’s very likely that amyloid is the trigger, but the process of Alzheimer’s disease does require other things that happen which we don’t entirely understand.”
Participants underwent a neuropsychological examination, and received magnetic resonance imaging, or MRI, and positron emission tomography, or PET, scans of their heads every 18 months for at least three years. As Alzheimer’s disease progresses, the pace of amyloid deposition slows, the researchers found.
The data indicate that there is a prolonged period in which amyloid beta is forming plaques in the brain without the symptoms of Alzheimer’s disease, the authors said. Even before dementia sets in, shrinkage in the part of the brain linked to memory and attention occurs about four years earlier, and memory is impaired about three years prior.
Early Signs
“We compared when you can first see changes on an MRI scan and on memory testing, and we can pick them up from about seven years before dementia,” Rowe said.
Extrapolating the data suggests beta amyloid deposition can lead to dementia in as few as 10 years, with an average of 19 years, he said. There is also a period in which the early stages of amyloid deposits are occurring though not detectable.
“The entire process is now getting up toward more than 25 years,” Rowe said. “This is much longer than people expected.”
Patients with tertiary education and those with bigger brains prior to the formation of amyloid deposits can tolerate higher levels of the errant protein, he said.
Rowe and colleagues are now studying potential therapies to stymie amyloid plaques before they have had a chance to damage and eventually kill brain cells. If successful, the use of PET scans -- which cost $1,500 to $3,500 apiece -- “will explode,” Rowe said.
‘Great Hope’
“You have a much greater chance of stopping a disease than trying to repair a brain that’s severely damaged,” he said. “This is the great hope now.”
Pfizer Inc. (PFE), Roche Holding AG (ROG), Eli Lilly & Co. (LLY), GlaxoSmithKline Plc (GSK), Elan Corp. and Prana Biotechnology Ltd. (PBT) are among drugmakers racing to develop treatments for Alzheimer’s. There have been 101 unsuccessful attempts since 1998, according to the Pharmaceutical Research and Manufacturers of America. Current therapies provide some temporary symptomatic improvement.
“The problem with Alzheimer’s disease is that you don’t have an effective therapy, but we can certainly make a better diagnosis with amyloid imaging -- be more precise about what’s going on with the patient and what their prognosis is -- but we can’t change the course of their disease,” Rowe said.
To contact the reporter on this story: Jason Gale in Melbourne at j.gale@bloomberg.net
To contact the editor responsible for this story: Bret Okeson at bokeson@bloomberg.net
http://www.bloomberg.com/news/2013-03-08/alzheimer-s-seen-on-scans-decades-before-dementia-study-shows.html
Thank you Renee
Funny trades today :)
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
Good advice!
Keep cool, if it drop to sub penny area, I don't think so (too cheap), I would buy millions....and all shareholders should do that.
Market Maker Surveillance Report. DVAX, FCX, PSSI, CIM, S, ILNS, Highest Net Sell Volume and Negative Price Friction For Tuesday, February 19th 2013
(M2 PressWIRE Via Acquire Media NewsEdge) BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3840 companies with "abnormal" market making, 3574 companies with positive Friction Factors and 2220 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dynavax Technologies Corp (NASDAQ:DVAX), Freeport-McMoRan Copper & Gold Inc (NYSE:FCX), PSS World Medical Inc (NASDAQ:PSSI), Chimera Investment Corp (NYSE:CIM), Sprint Nextel Corp (NYSE:S), INTELLECT NEUROSCIENCES INC (OTC:ILNS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below: Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction DVAX $-0.200 -6.35% 2,324,546 37.73% 3,820,560 62.01% -1,496,014 -74,801 FCX $-0.640 -1.81% 4,217,365 24.08% 5,561,373 31.76% -1,344,008 -21,000 PSSI $-0.020 -0.05% 659,139 19.62% 2,540,922 75.65% -1,881,783 -940,892 CIM $-0.080 -2.75% 6,449,791 29.35% 8,093,108 36.82% -1,643,317 -205,415 S $-0.010 -0.17% 5,441,805 29.37% 7,817,587 42.20% -2,375,782 -2,375,782 ILNS $-0.119 -88.15% 3,213,568 37.58% 5,337,046 62.42% -2,123,478 -178,444 Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have low price friction combined with more selling than buying (negative Net Volume) in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows DVAX down $-0.20000 with a Friction Factor of -74,801 and a Net Volume of -1,496,014. That means that it takes 74,801 more shares of selling than buying to drop DVAX by one penny. On Monday the Market Makers allowed the stock to move down on heavier selling than buying (low negative friction).
Dynavax Technologies Corp (NASDAQ:DVAX) - Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. The company's lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. It is also developing Universal Flu vaccine, which is in Phase Ib clinical trial for influenza prevention; DV-601 that is in Phase Ib clinical trial for the treatment of hepatitis B infection; AZD1419, which is in preclinical stage for asthma therapy; and DV1179 that is in Phase I trial for autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize toll-like receptor inhibitors; and research collaboration and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California..
Freeport-McMoRan Copper & Gold Inc (NYSE:FCX) - Freeport-McMoRan Copper & Gold Inc. engages in the exploration, mining, and production of mineral resources. The company primarily explores for copper, gold, molybdenum, cobalt hydroxide, silver, and other metals, such as rhenium and magnetite. It holds interests in various mines located in the Grasberg minerals district in Indonesia; Morenci minerals district in North America; South America; and Tenke Fungurume minerals district in the Democratic Republic of Congo. As of December 31, 2011, the company s consolidated recoverable proven and probable reserves included 119.7 billion pounds of copper, 33.9 million ounces of gold, 3.42 billion pounds of molybdenum, 330.3 million ounces of silver, and 0.86 billion pounds of cobalt. Freeport-McMoRan Copper & Gold Inc. was founded in 1987 and is headquartered in Phoenix, Arizona..
PSS World Medical Inc (NASDAQ:PSSI) - PSS World Medical, Inc. provides medical products and supplies, diagnostic equipment, healthcare information technology, pharmaceutical products, and professional and consulting services in the United States. The company operates in two segments, Physician Business and Extended Care Business. The Physician Business segment distributes approximately 164,000 products, such as disposable supplies, pharmaceuticals, and diagnostic and non-diagnostic equipment, as well as offers healthcare information technology and physician dispensing solutions to office-based physicians specializing in internal medicine, family practice, primary care, pediatrics, OB/GYN, cardiology, orthopedics, general practice, and other specialties; and operating under the ownership of private or public companies or acute care facilities. As of March 30, 2012, this segment operated a distribution network comprising 33 full-service distribution centers, 39 break-freight locations, 2 other operations-related facilities, and 2 redistribution facilities. The Extended Care Business segment distributes approximately 46,000 medical and related products, such as medical supplies, incontinent supplies and personal care items, enteral feeding supplies, point of care testing devices, wound care, home medical equipment, and other supplies to independent, regional, and national nursing home facilities; home health agencies; assisted living centers; hospices; and home medical equipment dealers. This segment also offers its own store brands, including Select Medical Products and other specialty brand products; Medicare Part B and Medicaid billing services to the nursing home and assisted living market; and consulting services to extended care providers. It operated a distribution network consisting of 18 full-service distribution centers, 10 break-freight locations, 2 other operations-related facilities, and 2 redistribution facilities. The company was founded in 1983 and is based in Jacksonville, Florida..
Chimera Investment Corp (NYSE:CIM) - Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and other asset classes. Its targeted asset classes include agency or non-agency RMBS; prime, jumbo prime, and Alt-A mortgage loans; first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, or industrial properties; and asset-based securities (ABS), including commercial mortgage-backed securities, debt and equity tranches of collateralized debt obligations, and consumer and non-consumer ABS. The company has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Investment Corporation was founded in 2007 and is based in New York, New York..
Sprint Nextel Corp (NYSE:S) - Sprint Nextel Corporation, together with its subsidiaries, offers wireless and wireline communications products and services to individual consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the United States Virgin Islands. It operates in two segments, Wireless and Wireline. The Wireless segment provides data transmission services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; mobile entertainment applications; and local and long distance wireless voice services, voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. This segment also provides customized design, development, implementation, and support for wireless services provided to large companies and government agencies, as well as sells accessories, such as carrying cases, hands-free devices, batteries, battery chargers, and other devices and accessories to subscribers, agents, and other third-party distributors for resale. The Wireline segment offers voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol, managed network services, voice over Internet protocol, session initiated protocol, and traditional voice services, as well as wholesale voice local and long distance, and digital voice services. This segment markets and sells its services primarily through direct sales representatives. The company offers its wireless and wireline voice and data transmission services under the Sprint, Nextel, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. It serves approximately 56 million customers. The company was founded in 1899 and is headquartered in Overland Park, Kansas..
INTELLECT NEUROSCIENCES INC (OTC:ILNS) - Intellect Neurosciences, Inc., a biopharmaceutical company, engages in the discovery and development of proprietary drug candidates for the treatment of Alzheimer s disease and other diseases associated with oxidative stress. The company s drugs are based on its immunotherapy platform technologies, ANTISENILIN, RECALL-VAX, and CONJUMAB-A. Its product candidates include OX1, an orally-administered, brain-penetrating, and naturally-occurring copper-binding small molecule, which has completed Phase-I clinical trial for the treatment of Alzheimer s disease; IN-NO1, a preclinical humanized monoclonal antibody designed to prevent the accumulation of amyloid beta in the brain of Alzheimer s patients; and RV 01 and RV02 that are preclinical active vaccines for the treatment of Alzheimer s disease. The company has license agreements with University of South Alabama Medical Science Foundation, New York University, AHP Manufacturing BV, and ViroPharma; and collaboration agreement with MRC Technology and the University California. Intellect Neurosciences, Inc. was founded in 2005 and is based in New York, New York..
About BUYINS.NET BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include: REGULATORY & COMPLIANCE NEWS Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO INVESTMENTS & TRADING SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
http://callcenterinfo.tmcnet.com/news/2013/02/20/6934418.htm
"While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF)."
http://finance.yahoo.com/news/novel-alzheimers-therapeutics-developer-says-130724320.html
SHORT SELLING, DEATH SPIRAL CONVERTIBLES, AND
THE PROFITABILITY OF STOCK MANIPULATION
http://www.sec.gov/comments/s7-08-08/s70808-318.pdf
When Does Short Selling Become Manipulation?
http://www.klgates.com/files/tempFiles/901e34d6-b3ee-4ac4-bdad-3b6cabd7060b/Alert_SEC_ShortSelling.pdf
March 1, 2013
Short Sell Volume 51,62%; Sell Volume 50,39%;
Buy: 283.200
49,61%
Sell: 287.700
50,39%
RegularVol: 570.900
100%
ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
Short Volume 294.700
51,62%
RegularVol: 570.900
100%
http://otcshortreport.com/index.php?index=ilns&action=view
Short Volume Ratio 0,516
http://shortvolume.com/
I would like to ask you for your analytical statement please.
Short Sell Volume 51,62%; Sell Volume 50,39%;
Buy: 283.200
49,61%
Sell: 287.700
50,39%
RegularVol: 570.900
100%
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
Short Volume 294.700
51,62%
RegularVol: 570.900
100%
http://otcshortreport.com/index.php?index=ilns&action=view
Short Volume Ratio 0,516
http://shortvolume.com/
Links on ILNS
http://www.fool.com/investing/general/2013/02/28/why-is-the-blockbuster-model-breaking.aspx
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85157418
http://netprnews.com/trend-analysis-report-on-microelectronics-technology-green-innovations-intellect-neurosciences-treaty-energy/1211563/
http://seekingalpha.com/article/1077121-star-scientific-and-therapeuticsmd-2-overvalued-pseudo-pharmaceuticals
Buy: 283.200
49,61%
Sell: 287.700
50,39%
RegularVol: 570.900
100%
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
Short Volume 294.700
51,62%
RegularVol: 570.900
100%
http://otcshortreport.com/index.php?index=ilns&action=view
Short Volume Ratio 0,516
http://shortvolume.com/
Short Interest: What It Tells Us
April 23 2011| Filed Under » New York Stock Exchange, Short Selling
As some of you may already know, short selling allows a person to profit from a falling stock. The existence of this ability to short sell a stock should not come as a surprise as stock prices are constantly rising and falling. Thus, there are brokerage departments and firms whose sole purpose is to research deteriorating companies that are prime short-selling candidates. These firms pore over financial statements looking for weaknesses that the market may not have discounted yet or a company that is simply overvalued. One factor they look at is called short interest, which serves as a market-sentiment indicator. We'll cover it in detail in this article.
Tutorial: How To Use Short Selling
A Review of Short Selling
Essentially, short selling is the opposite of buying stocks - it's the selling of a security that the seller does not own, done in the hope that the price will fall. If you feel a particular security's price, let's say the stock of a struggling company, will fall, you can borrow the stock from your broker-dealer, sell it and get the proceeds from the sale. If, after a period of time, the stock price declines, you can "close out" the position by buying the stock on the open market at the lower price, return the stock to your dealer-broker and realize a gain.
The catch is, if the stock price rises, you lose money because you have to buy the stock back at a higher price. In addition, your broker-dealer can demand that the position be closed out at any time, regardless of the stock price. However, this demand typically occurs only if the dealer-broker feels that the creditworthiness of the borrower is too risky for the firm.
Short Interest
Short interest is the total number of shares of a particular stock that have been sold short by investors but have not yet been covered or closed out. This can be expressed as a number or as a percentage.
When expressed as a percentage, short interest is the number of shorted shares divided by the number of shares outstanding. For example, a stock with 1.5 million shares sold short and 10 million shares outstanding has a short interest of 15% (1.5 million/10 million = 15%).
Most stock exchanges track the short interest in each stock and issue reports at month's end. These reports are great for traders because by showing what short sellers are doing, they allow investors to gauge overall market sentiment surrounding a particular stock. Alternatively, most exchanges provide an online tool to calculate short interest for a particular security.
Reading Short Interest
A large increase or decrease in a stock's short interest from the previous month can be a very telling indicator of investor sentiment. Let's say that Microsoft's short interest increased by 10% in one month. This means that there was a 10% increase in the number of people who believe the stock price will decrease. Such a significant shift provides good reason for investors to find out more. We would need to check the current research and any recent news reports to see what is happening with the company and why more investors are selling its stock.
A high short-interest stock should be approached with extreme caution but not necessarily avoided at all cost. Short sellers (like all investors) aren't perfect and have been known to be wrong from time to time.
In fact, many contrarian investors use short interest as a tool to determine the direction of the market. The rationale is that if everyone is selling, then the stock is already at its low and can only move up. Thus, contrarians feel that a high short-interest ratio (which we will discuss below) is bullish - because eventually there will be significant upward pressure on the stock's price as short sellers cover their short positions (i.e. buy back the stocks they borrowed to return to the lender). (Learn more in Can Perpetual Contrarians Profit As Traders?)
Short-Interest Ratio
The short-interest ratio is the number of shares sold short (short interest) divided by average daily volume. This is often called the "days-to-cover ratio" because it determines, based on the stock's average trading volume, how many days it will take short sellers to cover their positions if positive news about the company lifts the price.
Try Currency Trading Risk-Free at FOREX.com
Again, let's assume Microsoft has a short interest of 75 million shares, while the average daily volume of shares traded is 70 million. Doing a quick and easy calculation (75,000,000/70,000,000), we find that it would take 1.07 days for all of the short sellers to cover their positions. The higher the ratio, the longer it will take to buy back the borrowed shares - an important factor upon which traders or investors decide whether to take a short position. Typically, if the days to cover stretch past eight or more days, covering a short position could prove difficult.
The NYSE Short Interest Ratio
The New York Stock Exchange short-interest ratio is another great metric that can be used to determine the sentiment of the overall market. The NYSE short-interest ratio is the same as short interest except it is calculated as monthly short interest on the entire exchange divided by the average daily volume of the NYSE for the last month.
For example, suppose there are five billion shares sold short in August and the average daily volume on the NYSE for the same period is one billion shares per day. This gives us a NYSE short-interest ratio of five (five billion /one billion). This means that, on average, it will take five days to cover the entire short position on the NYSE. In theory a higher NYSE short interest ratio indicates a more bearish sentiment towards the exchange.
Short Squeeze
Some bullish investors see high short interest as an opportunity. This outlook is based on the short interest theory. The rationale is, if you are short selling a stock and the stock keeps rising rather than falling, you'll most likely want to get out before you lose your shirt. A short squeeze occurs when short sellers are scrambling to replace their borrowed stock, thereby increasing demand and decreasing supply, forcing prices up. Short squeezes tend to occur more often in smaller cap stocks, which have a very small float (supply), but large caps are certainly not immune to this situation.
If a stock has a high short interest, short positions may be forced to liquidate and cover their position by purchasing the stock. If a short squeeze occurs and enough short sellers buy back the stock, the price could go even higher. Unfortunately, however, this is a very difficult phenomenon to predict. (Find out how this strategy is used in Short Squeeze The Last Drop Of Profit From Market Moves.)
The Bottom Line
Although it can be a telling indicator, an investment decision should not be based entirely on a stock's short interest; however, investors often overlook this ratio despite its widespread availability. Unlike the fundamentals of a company, the short interest requires little or no calculations. Half a minute of time to look up short interest can help provide valuable insight into what sentiment investors have toward a particular company or exchange.
http://www.investopedia.com/articles/01/082201.asp#axzz2MT35gMFI
Remember...
Letter to Shareholders
NEW YORK, Aug. 7, 2012 (GLOBE NEWSWIRE)
"Intellect Neurosciences has carefully planned a survival strategy to ensure its continued viability. In doing so, we have remained ahead of the curve with respect to next-generation therapies by creating multiple distinctive platform technologies that generate drug candidates for a wide variety of diseases. We also have protected our work through an extensive global patent portfolio. Consequently, Intellect has a significant value proposition in our preclinical programs and in our OX1 product, which was licensed to ViroPharma and is anticipated to enter Phase 2 clinical trials in patients with Friedreich's Ataxia. With the anticipated completion of Phase 2 trials by 2015, Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, upon regulatory approval, royalties from sales in this orphan indication over many years. Prior to 2015, new licensing deals for our pipeline programs could yield substantial non-dilutive capital.
Thank you for your continued support of Intellect Neurosciences and our important mission to create a world without Alzheimer's disease and other debilitating neurodegenerative diseases.
Sincerely,
Daniel Chain, Ph.D.
Chairman & CEO"
http://ir.stockpr.com/intellectns/press-releases/detail/783/intellect-neurosciences-issues-letter-to-shareholders
Thanks for sharing...
"While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF)."
"However, we are currently focused on optimizing CONJUMAB-A using our own antibody IN-N01 which targets the N-terminus of Aß. We believe IN-N01 to be superior to bapineuzumab because of its reduced potential to cause inflammation which results from our reengineering of the originally produced IG1 class antibody into an IgG4 class antibody. We believe this safety feature is particularly important for antibodies that bind Aß aggregates and not just soluble single monomeric Aß. Among several potential indications, we have decided to focus on age related macular degeneration (AMD) for proof of concept studies since AMD and AD share several similarities while the eye offers less challenge for delivering the drug. "
"An important step in establishing proof-of-principle was the initial data generated through our collaboration with iNovacia to evaluate compounds synthesized by Lonza for Intellect. The data demonstrated the conjugation of the antioxidant molecule to an amino acid does not reduce its antioxidant activity. Pending adequate financial resources, these studies, which are almost complete, will allow us to select a drug candidate to take into development, providing the trigger for us to move forward with LONZA into an expanded manufacturing project, bringing us closer to the submission of an Investigational New Drug application."
Melatonin and Alzheimer's Disease
Improving Sleeplessness and Sundowning With Melatonin
From John Casey
Updated August 05, 2008
LifeWire) - Alzheimer's disease is a devastating illness, but unique treatments like the hormone melatonin may be able to improve difficult symptoms such as sleeplessness and sundowning.
Sundowning refers to behavioral disturbances that are fairly common in Alzheimer's disease and tend to occur in the early evening. For reasons that aren't entirely clear, many people with Alzheimer's exhibit increased confusion, anxiety, agitation and even aggression at the end of the day. Luckily, there's evidence that melatonin can help with sundowning and related sleep disturbances.
Alzheimer's and "Sundowning"
According to the Alzheimer's Association, nearly a fifth of individuals with Alzheimer's will experience periods of sundowning, usually in the middle stages of the disease. Sundowning takes a toll on those who have Alzheimer's and contributes greatly to caregiver stress and fatigue. It reportedly plays a major role in decisions to move those with Alzheimer's from home care to nursing homes.
Melatonin has many roles in the body, but it is particularly important in sleep regulation. Melatonin is produced in the brain, specifically by the pineal gland. This gland releases its peak level of melatonin at dusk, and the hormone appears to be instrumental in the cascade of changes that we call falling asleep.
Alzheimer's and Melatonin
Research has long established that melatonin levels naturally decrease with age, but people with Alzheimer's disease have especially low levels -- sometimes only half as much as people of the same age who don't have the disease. Also, sleep disturbances are frequently a symptom of Alzheimer's. In recent years, a number of studies have reported benefits of supplemental melatonin, not only for reducing Alzheimer's-related sleep problems, but for sundowning as well.
Melatonin may also have further benefits. It's a powerful antioxidant, acting to counter harmful chemical reactions that can damage cells. It appears to have specific neuroprotective qualities, meaning that it helps protect nerve and brain cells from damage. There's also evidence that having an insufficiency of melatonin plays a role in depression.
Some studies suggest that the hormone can improve mild cognitive impairment, although researchers emphasize that the effect is limited and that melatonin isn't a "cure" for full-blown Alzheimer's disease. Some researchers caution that the impact of the hormone would be relatively less in late-stage Alzheimer's.
On the positive side, melatonin has few if any side effects, in large part because it's processed and removed from the body very quickly. However, that quality and the multiplicity of its effects make melatonin less than ideal as a medication.
Researchers have begun developing "melatoninergic" or melatonin-type drugs that are longer-acting and have more specific targets. Rozerem (ramelteon) has won FDA approval for long-term treatment of sleep disturbances. Another drug, Valdoxan (agomelatine), is meant to treat major depressive disorders and is also undergoing clinical trials for FDA approval.
Thus far, no melatonin-type medications have been developed specifically for Alzheimer's disease or sundowning.
What You Can Do
Since melatonin is classified as a supplement, it's available without a prescription. But before you give the hormone to someone with Alzheimer's, you should consult his or her physician, who'll be able to determine whether it makes sense and fits the person's symptoms. Studies of melatonin for treating Alzheimer's have reported benefits from doses of 3 to 9 mg of melatonin per day.
http://alzheimers.about.com/lw/Health-Medicine/Alternative-treatments/Melatonin-and-Alzheimers-Disease.htm
SEC have to stop manipulation! Buys shown as sell volume!
Bought another 200000, one trade - shown as sell volume!
Thank you for your efforts, Summary Judgment, News and Publicity will have a significant impact on ILNS that will respond to catalytic activity.
ILNS AT THE TURNING POINT
You are absolutely right Gr8White.
IMO
"Intellect was selected to give a presentation at BIOEUROPE in Barcelona March 11-13 and I have scheduled several meetings with potential partners."
http://www.ebdgroup.com/bes/presenters/prs_comps.php?carousel_staple
http://www.ebdgroup.com/bes/index.php
Thank you!
Yes you know how the NY courts work, so I'm asking you. It's extremly hard for me because I'm from Austria. But I spend a lot, a lot of time to read a lot papers about neurodegenerative diseases and Dr. Chain.... I can't believe it...!antioxidants!... and all these improved technology!! Thank you for your endless research and never ever give up Dr. Chain!
Any news from yesterday?
Interesting Statement from ILNS Yahoo board:
"I AM SHORTING & PAID TO MANIPULATE.. SO YOU MF BETTER LISTEN! SO YOU SELL"
"I told you to short this you son..o.f pps and mm will get you"
"You better not buy this company... I will kick your #$%$"
"i TOLD YOU TO SELL NOW...."
"I AM PAID TO BASH THIS COMPANY MUST KEEP PRICE DOWN"
"I don't care if there worth 2-3 bucks ..keep down"
http://finance.yahoo.com/mbview/userview/?&u=teddds8poo&bn=faee84cc-9764-3fc4-b8fc-3d0136af263c
And why are my buys have been shown as a sell volume?
It's implausible to be a typo at the last minute.
Short volume 0.022m.
Short volume 0.022m?
So a buy could be shown as a sell?
Have you ever met an AD patient?
I have one in my family
"We continue to suffer from an enormously undervalued stock which I believe is the result of a few shareholders who for some reason are not invested in the long-term growth of the company."
Haven't had time...
Financial Times (London)
Andrew Jack
Andrew Jack writes for the Financial Times
on pharmaceuticals and health globally.
https://twitter.com/AJack
The Times of India,
Times Annexe, 1st Floor,
9-10, Bahadurshah Zafar Marg,
New Delhi - 110002, India
Tel : +91-11-42512141 / 42512142 / 42512275 / 42512143 / 42512858
Fax : +91-11-23701291
tss@timesgroup.com
http://economictimes.indiatimes.com
The Indian Express Online Media (Pvt) Ltd
9&10, Bhadur Shah Zafar Marg,
Express Building, ITO
New Delhi -110002
India
FAX US AT+ 91-11-23702141
EMAIL US AT editor@expressindia.com
PHONE+ 91-9891968097
Srinivasan Sivabalan
Current:
Stocks Editor (Europe) at Bloomberg
Past:
Senior Editor at FORBES INDIA magazine - A Network18 venture, Editor - Knowledge & Technology at The Economic Times, National Service Desk at Reuters, Correspondent at The Associated Press, Correspondent at BridgeNews, Correspondent at Press Trust of India, Copy Editor cum Business Correspondent at The Economic Times, Correspondent at Ananda Vikatan Tamil magazine
https://twitter.com/madraschap
http://www.linkedin.com/pub/dir/?first=Srinivasan&last=Sivabalan&search=Go
http://washpost.bloomberg.com/Story?docId=1376-MBENRB1A74E901-5QSVGAVF7H3AO64IKGFDRPSO7T
http://washpost.bloomberg.com/Story?docId=1376-MI3P2D6TTDSO01-1IHQRM2328V8K12I4ER2Q6B2L3
Business Standard
Delhi Office Address
Business Standard Limited
Nehru House,
4, Bahadur Shah Zafar Marg,
New Delhi - 110002
Tel: 91 - 11 - 23720202-10
Fax: 91 - 11 - 23720201/23353454
letters@business-standard.com
I smell new market maker here.
An important step in establishing proof-of-principle was the initial data generated through our collaboration with iNovacia to evaluate compounds synthesized by Lonza for Intellect. The data demonstrated the conjugation of the antioxidant molecule to an amino acid does not reduce its antioxidant activity. Pending adequate financial resources, these studies, which are almost complete, will allow us to select a drug candidate to take into development, providing the trigger for us to move forward with LONZA into an expanded manufacturing project, bringing us closer to the submission of an Investigational New Drug application.